Le Lézard
Classified in: Health
Subject: SVY

Negative Pressure Wound Therapy Market Research Report - Global Industry Analysis and Growth Forecast to 2024


DUBLIN, Sept. 20, 2019 /PRNewswire/ -- The "Negative Pressure Wound Therapy Market Research Report: By Product, Wound Type, End-User, Geographical Insight - Global Industry Analysis and Growth Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The negative pressure wound therapy (NPWT) market is expected to grow at a 6.6% CAGR during the forecast period and account for $3,001.3 million revenue by 2024.

The growing geriatric population, increasing diabetes prevalence, and high rate of caesarean sections, which require NPWT devices, are the key driving factors of the market.

Based on end user, the categories of the negative pressure wound therapy market are homecare settings, hospitals and clinics, and others. Advancing at a 6.9% CAGR, homecare settings are expected to be the fastest growing category during the forecast period. The growth of this end-user category can be attributed to technological developments, which make getting medical care at home easier, and the growing preference for home healthcare for better comfort.

Furthermore, the hospital end-user category of the negative pressure wound therapy market is bifurcated into out-patient and in-patient sub-categories. Between the two, the in-patient sub-category is expected to exhibit faster growth and generate larger revenue during the forecast period. This would be due to the increasing number of diseases which require prolonged care, thereby resulting in high NPWT usage. This sub-category is expected to advance at a 7.1% CAGR during the forecast period compared to 5.3% in the historical period.

The negative pressure wound therapy market is classified into acute and chronic wounds, based on wound type. The chronic wound classification is further categorized into diabetic foot, venous, and pressure ulcers. As NPWT devices are mostly utilized for venous ulcer treatment, this category is predicted to hold a 61.1% share in the market by 2024. The major reason for the prevalence of venous ulcers is the rising incidence of varicose veins in people.

Furthermore, the categories of the acute wound classification are burns, surgical wounds, and others. The surgical wound category has been accounting for the largest market share due to the increasing number of surgeries worldwide.

Owing to the extensive wound epidemiology in the country, the U.S. negative pressure wound therapy market is expected to generate a revenue of $790.5 million by 2024, witnessing a 6.7% CAGR during the forecast period. The chronic wound prevalence in the country rose to 6,362,965 cases in 2018 from 5,788,966 cases in 2016.

This can be attributed to the growing number of diabetic patients and geriatric population. The risk of developing diabetic foot ulcers increases with the severity of diabetes. Moreover, the older population is susceptible to diabetes, which may result in chronic wounds, thereby making age a major risk factor for developing chronic wounds. In the U.S., 50.1 million people were aged 65 or above in 2017, growing from 42.5 million in 2012, as per the World Bank.

The prominent players in the negative pressure wound therapy market are Braun Melsungen AG, BSN medical GmbH, Genadyne Biotechnologies Inc., Carilex Medical, Shandog Wego Newlife Medical Device, Cork Medical LLC, Smith & Nephew PLC, and Mlnlycke Health Care AB.

Companies Mentioned


For more information about this report visit https://www.researchandmarkets.com/r/1r53cn

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:


Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: